Trial Profile

Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Single-arm, Single-center Clinical Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olverembatinib (Primary) ; Prednisone (Primary) ; Venetoclax (Primary) ; Vincristine (Primary)
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

03 Jun 2025 Status changed from recruiting to completed.
12 Dec 2023 Early results (n=31) assessing efficacy and safety of olverembatinib combined with venetoclax in patients with acute lymphoblastic leukemia, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
02 Nov 2023 Results presented in the Ascendis Pharma Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com